Patents Examined by Laura Cross
  • Patent number: 5877202
    Abstract: The present invention relates to novel indole derivatives useful in down-regulating estrogen receptor expression. Also included are methods for the treatment of neoplasms or of controlling the growth of a neoplasm in a patient afflicted with a neoplastic disease, especially estrogen-dependent neoplasms such as those associated with breast, ovarian and cervical tissue. Another embodiment of the present invention is a method of prophylactically treating a patient at risk of developing a neoplastic disease state. Also provided is a method for treating autoimmune diseases. Also included are pharmaceutical compositions of the novel indole derivatives.
    Type: Grant
    Filed: January 31, 1996
    Date of Patent: March 2, 1999
    Inventors: Alan J. Bitonti, Ian A. McDonald, Francesco G. Salituro, Jeffrey P. Whitten, Esa T. Jarvi, Paul S. Wright
  • Patent number: 5834499
    Abstract: A 5-HT.sub.3 receptor against containing a thiazole derivative as the effective ingredient is provided and is represented by the Formula (I): ##STR1## wherein the A ring is substituted or unsubstituted and represents a benzene or a heterocyclic ring with one or two heteroatoms;one of L.sub.1 or L.sub.
    Type: Grant
    Filed: August 26, 1996
    Date of Patent: November 10, 1998
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Kiyoshi Iwaoka, Hideki Anan, Naoki Imanishi, Kenichi Kazuta, Hiroyuki Koshio, Takeshi Suzuki, Hirotsune Itahana, Hiroyuki Ito, Keiji Miyata, Mitsuaki Ohta
  • Patent number: 5808080
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: September 15, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, David Andrew Neel, Mark Alan Winter
  • Patent number: 5792781
    Abstract: A compound represented by the general formula: ##STR1## wherein R.sup.1 and R.sup.2 denote a halogen atom or hydrogen atom; R.sup.3 means a hydrogen atom or lower alkyl group; l, r and m stand for 0 or 1; A is N or CH; W denotes an aromatic ring or a condensed ring thereof; X means another aromatic ring, an alkanediyl group, an alkenediyl group, or an alkynediyl group; Y stand for --S--, etc.; Z denotes a hydrogen atom, etc., or a salt thereof, and intermediates thereof or a salt thereof as well as processes for the preparation thereof, and pharmaceutical composition suitable for use as an antifungal agent.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: August 11, 1998
    Assignee: Eisai Co., Ltd.
    Inventors: Toshihiko Naito, Katsura Hata, Yumiko Kaku, Akihiko Tsuruoka, Itaru Tsukada, Manabu Yanagisawa, Toshio Toyosawa, Kazumasa Nara
  • Patent number: 5783589
    Abstract: 4-R.sup.4 -R.sup.5 -2-Saccharinylmethyl aryl and aryloxy acetates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R.sup.4 -R.sup.5 -2-halomethylsaccharin with an aryl or aryloxyacetic acid in the presence of an acid-acceptor.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: July 21, 1998
    Assignee: Sanofi
    Inventors: Lee Hamilton Latimer, Richard Paul Dunlap
  • Patent number: 5776971
    Abstract: Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 7, 1998
    Assignee: G.D. Searle & Co.
    Inventors: Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Michael L. Vazquez, James A. Sikorski, Balekudru Devadas, Srinivasan Nagarajan, David L. Brown, Joseph J. McDonald
  • Patent number: 5776984
    Abstract: The present invention provides a compound of the formula: ##STR1## Such compounds are useful for inhibiting prostaglandin synthesis. Pharmaceutical compositions and methods for inhibiting prostaglandin synthesis are also disclosed.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: July 7, 1998
    Assignee: Abbott Laboratories
    Inventors: Joseph F. Dellaria, Todd H. Gane
  • Patent number: 5773462
    Abstract: Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are provided. Antiviral biflavanoid derivatives and salt forms thereof, e.g., robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compositions which include the antiviral biflavanoids, derivatives or salts thereof are also provided. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compounds, derivatives or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g., influenza A and B; hepatitis, e.g., hepatitis B; human immunodeficiency virus, e.g., HIV-1; Herpes viruses (HSV-1 and HSV-2); Varicella Zoster virus (VZV); and measles.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: June 30, 1998
    Assignee: MediChem Research, Inc.
    Inventors: Yuh-Meei Lin, Michael T. Flavin, Ralph Schure, David E. Zembower, Gen-Xian Zhao
  • Patent number: 5773460
    Abstract: The present invention relates to novel photoactivable rhodamine derivatives for enhancing high quantum-yield production and singlet oxygen generation upon irradiation with light while maintaining desirable differential retention of rhodamine between normal and cancer cells. Representative derivatives are2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride; 2-(4, 5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid ethyl ester hydrochloride; 2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid octyl ester hydrochloride; 2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride; 2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride; and photoactivable derivatives thereof.
    Type: Grant
    Filed: July 1, 1996
    Date of Patent: June 30, 1998
    Assignee: Universite De Montreal
    Inventors: Louis Gaboury, Luc Villeneuve, Richard Giasson, Tiechao Li, Ajay Kumar Gupta
  • Patent number: 5773437
    Abstract: The present invention relates to alkylenediamine derivatives which relieve urinating contraction and therefore are of value as active ingredients of therapeutic agents for treating dysuria.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: June 30, 1998
    Assignee: Nippon Chemiphar Co., Ltd.
    Inventors: Mitsuo Masaki, Norihisa Miyake, Atsushi Tendo, Michiko Ishida, Haruhiko Shinozaki, Yutaka Nomura, Yasunori Goto
  • Patent number: 5763652
    Abstract: A nitrile compound or an amide compound is hydrolyzed in the presence of an inorganic acid or other acidic catalyst or an alkali metal hydroxide or other basic catalyst, and the by-produced ammonium salt of the acidic catalyst or the produced salt of a carboxylic acid and a base is electrodialysed to form an acid and ammonia or aqueous ammonia, or to form a base and ammonia. The obtained acid or base may be recycled as a catalyst for the hydrolysis of the nitrile compound or amide compound, and the obtained ammonia is reutilized as a nitrogen source for the nitrile compound or amide compound. Such amide compound may be produced by hydration of a nitrite compound in the presence of a manganese oxide.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: June 9, 1998
    Assignee: Daicel Chemical Industries, Ltd.
    Inventors: Masato Kawabe, Kenichi Yamamoto, Kazuyuki Matsuoka
  • Patent number: 5756533
    Abstract: Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 26, 1998
    Assignee: G.D. Searle & Co.
    Inventors: Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Michael L. Vazquez, James A. Sikorski, Balekudru Devadas, Srinivasan Nagarajan, David L. Brown, Joseph J. McDonald
  • Patent number: 5750550
    Abstract: 2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
    Type: Grant
    Filed: September 15, 1995
    Date of Patent: May 12, 1998
    Assignee: Sanofi
    Inventors: Michael A. Eissenstat, Gee-Hong Kuo, Ranjit C. Desai, Dennis J. Hlasta, John J. Court
  • Patent number: 5747515
    Abstract: Novel heterocyclic compounds having a structure according to general formula (1), pharmaceutically acceptable acid addition salts and solvates thereof are described as having a pharmacological profile showing potential for treatment of acute and chronic neuropsychiatric disorders which are known as progressively deteriorating conditions leading to neuronal cell death and dysfunction. Pharmaceutical formulations are described as containing said therapeutic compounds.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: May 5, 1998
    Assignee: Astra Aktiebolag
    Inventors: Robin Bernad Boar, Alan John Cross, Duncan Alastair Gray, Richard Alfred Green
  • Patent number: 5747513
    Abstract: Compounds of the formula: ##STR1## wherein R is a hydrogen atom or an OY group; R.sub.1 is a hydrogen atom or in OY' group; R.sub.2 is a hydrogen atom or an OY" group; provided that at lent one among R, R.sub.1 and R.sub.2 is hydrogen but R, R.sub.1, and R.sub.2 are not contemporaneously hydrogen atoms and R.sub.1 and R.sub.2 are not contemporaneously OY' or OY" groups respectively; m is an integer 1 or 2; n is an integer 3 to 8; p is an integer 2, 3, or 4; R.sub.3 is a hydrogen atom or a C.sub.1 -C.sub.4 alkyl; R.sub.4 is a phenyl optionally substituted by halogen atom or a C.sub.1 -C.sub.3 alkyl or alkoxy group or a 5- or 6- membered heteroaryl containing one or more heteroatoms selected from oxygen, nitrogen and sulphur, optionally substituted by halogen atoms, hydroxy groups, C.sub.1 -C.sub.3 alkyl or alkoxy groups; X is CH.sub.2, NH, S, SO, SO.sub.2, CO, CF.sub.2, O and, when R.sub.4 is a 5- or 6- membered heteroaryl, X can be also a single bond. Pharmaceutically acceptable salts are described.
    Type: Grant
    Filed: April 30, 1996
    Date of Patent: May 5, 1998
    Assignee: Zambon Group, S.P.A.
    Inventors: Stefania Montanari, Paolo Cavalleri, Francesco Santangelo
  • Patent number: 5744609
    Abstract: A method for producing an alkylthiobenzamide by carrying out a reaction of a halobenzamide with an alkanethiol in the presence of a base in a heterogeneous solvent; a method for producing an alkylsulfinylbenzamide by carrying out a reaction of an alkylthiobenzamide with a halogen in a heterogeneous solvent; a method for producing an alkylsulfinylbenzamide by carrying cut a reaction of a halobenzamide with an alkanethiol in the presence of a base in a heterogeneous solvent and a subsequent reaction with a halogen; and a method for producing a 1,2-benzisothiazol-3-one by carrying out a reaction of a 2-(alkylthio)benzamide with a halogenating agent.
    Type: Grant
    Filed: April 7, 1997
    Date of Patent: April 28, 1998
    Assignees: Sumitomo Seika Chemicals Co., Ltd., Sumitomo Chemical Co., Ltd.
    Inventors: Hirokazu Kagano, Hiroshi Goda, Shigeki Sakaue
  • Patent number: 5739344
    Abstract: An aminoarylaminoarazole can be prepared by a process comprising the steps of condensing a condensable nitroarylcarbonyl compound with an aminonitroarylol, an aminonitroarylthiol, or a triaminonitroarene to form a dinitroanilide, then reducing and cyclizing the dinitroanilide under such conditions to form the aminoarylaminoarazole. The aminoarylaminoarazole is useful in making PIBX polymers.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: April 14, 1998
    Assignee: The Dow Chemical Company
    Inventor: R. Garth Pews
  • Patent number: 5736747
    Abstract: Organic compounds having at least one ethylenically-unsaturated group are described, the organic compounds being suitable for use in coatable compositions as reactive diluents; compounds of the invention preferably have a divalent organic linking moiety devoid of reactive groups other than optional ethylenically-unsaturated groups, and a polar organic moiety and are particularly adept in solubilizing aminoplast resins having radiation-curable pendant groups.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: April 7, 1998
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Ernest L. Thurber, Eric G. Larson, Alan R. Kirk, Gregg D. Dahlke
  • Patent number: 5725806
    Abstract: A method of stabilizing non-halogen containing 3-isothiazolone microbicides against chemical degradation by the introduction of aromatic disulfide compounds (except 2,2'-dithiobisbenzoic acid) is disclosed.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: March 10, 1998
    Assignee: Rohm and Haas Company
    Inventor: Tirthankar Ghosh
  • Patent number: 5714497
    Abstract: The subject of the invention is the compounds of formula I ##STR1## in which Ar.sub.1 represents naphtyl, phenyl, quinolyl or isoquinolyl optionally substituted;Ar.sub.2 represents a phenyl or thienyl optionally substituted;R.sub.1, R.sub.2 and R'.sub.2 are independently of each other, H or (C.sub.1 -C.sub.4)alkyl;R.sub.1 represents nothing and N is attached to Ar.sub.2, and optionally R.sub.2 and R'.sub.2 form a double bond;or R.sub.1 or R.sub.2 is attached to Ar.sub.2 and represents a (C.sub.1 -C.sub.3)alkylene;R.sub.3 and R.sub.4, which are identical or different, represent H, (C.sub.1 -C.sub.4)alkyl or form, with the nitrogen atom to which they are attached, a (C.sub.5 -C.sub.7) saturated heterocycle selected from pyrrolidine, piperidine and hexahydroazepine;Z.sub.1 represents a (C.sub.1 -C.sub.12)alkylene, optionally interrupted or extended by a (C.sub.5 -C.sub.7)cycloalkyl or phenyl.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 3, 1998
    Assignee: SANOFI
    Inventors: Bernard Christophe, Loic Foulon, Alain Pellet, Claudine Serradeil-Le-Gal, Gerard Valette